mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development

by A. A. Ilyichev, L. A. Orlova, S. V. Sharabrin, L. I. Karpenko
Published 2020-12-01

EPIDEMIOLOGIC FEATURES OF CLUSTERED MORBIDITY CAUSED BY ENTEROVIRAL INFECTIONS IN THE URAL FEDERAL DISTRICT AND WESTERN SIBERIA IN 2017

by A. V. Alimov, A. V. Rezaikin, Yu. Yu. Burtseva, P. S. Usoltseva, S. V. Sharabrin
Published 2018-12-01

Construction and Immunogenicity of Modified mRNA-Vaccine Variants Encoding Influenza Virus Antigens

by Ekaterina V. Starostina, Sergei V. Sharabrin, Denis N. Antropov, Grigory A. Stepanov, Georgiy Yu. Shevelev, Anna E. Lemza, Andrey P. Rudometov, Mariya B. Borgoyakova, Nadezhda B. Rudometova, Vasiliy Yu. Marchenko, Natalia V. Danilchenko, Anton N. Chikaev, Sergei I. Bazhan, Alexander A. Ilyichev, Larisa I. Karpenko
Published 2021-05-01

Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate

by Larisa I. Karpenko, Andrey P. Rudometov, Sergei V. Sharabrin, Dmitry N. Shcherbakov, Mariya B. Borgoyakova, Sergei I. Bazhan, Ekaterina A. Volosnikova, Nadezhda B. Rudometova, Lyubov A. Orlova, Inna A. Pyshnaya, Boris N. Zaitsev, Natalya V. Volkova, Mamedyar Sh. Azaev, Anna V. Zaykovskaya, Oleg V. Pyankov, Alexander A. Ilyichev
Published 2021-01-01